{"id":"W4401406952","doi":"10.1136/jitc-2024-008872","title":"Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden","year":2024,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Eli Lilly and Company; Ono Pharmaceutical; Astellas Pharma; Eisai; Department of Science and Technology, Ministry of Science and Technology, India; MacroGenics; Genentech; Actuate Therapeutics; Pfizer; Incyte; Mylan; BeiGene; Clovis Oncology; National Medical Research Council; Exelixis; Karyopharm Therapeutics; Daiichi Sankyo Europe; Gilead Sciences; Sanofi; GlaxoSmithKline; Amgen; Astex Pharmaceuticals; Medical Research Council; Les Laboratories Pierre Fabre; AstraZeneca; Samsung; Bristol-Myers Squibb","keywords":"Nivolumab; Ipilimumab; Medicine; Metastatic melanoma; Oncology; Internal medicine; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001157486,0.0004448255,0.002377942,0.0006302031,0.000113008,0.00007260801,0.0004828515,0.00006811255,0.00135124],"category_scores_gemma":[0.0000773896,0.0002723063,0.0002972491,0.0007958537,0.0003199609,0.0005052002,0.00003048383,0.0003346498,6.60258e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005572509,"about_ca_system_score_gemma":0.002232803,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001865493,"about_ca_topic_score_gemma":0.0004179345,"domain_scores_codex":[0.9958058,0.0002324797,0.002199579,0.0004248468,0.0009287426,0.0004085441],"domain_scores_gemma":[0.9968712,0.0005452753,0.001358089,0.0003941681,0.0007377929,0.00009351686],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8752655,0.004210545,0.000207528,0.0005023167,0.005138872,0.00006094578,0.005108115,0.0007111194,0.005362777,0.00001834993,0.0001531506,0.1032608],"study_design_scores_gemma":[0.9519186,0.03310514,0.001255152,0.003097658,0.0006304051,0.00008595141,0.002535517,0.001380461,0.004513715,0.0001897168,0.000887756,0.0003999064],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9830283,0.009431964,0.0004883254,0.0002478408,0.0006323524,0.005899199,0.0002356837,0.00001959673,0.00001674632],"genre_scores_gemma":[0.9930383,0.00198786,0.002727763,0.0001642541,0.0001041882,0.0006691697,0.00002734567,0.000136756,0.001144361],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1028609,"threshold_uncertainty_score":0.9999729,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03115629800748777,"score_gpt":0.3873314010086448,"score_spread":0.356175103001157,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}